Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -29.32% is 122% below its 2-year average of -13.18%, near the low end of its 2-year range (-39.49%–0.31%).
70.03% below its 12-month average of -17.24%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-03-31): 0.31%.
EBITDA MARGIN
-29.32%
EBITDA MARGIN AVG TTM
-17.24%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-70.03%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$112.05M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.99M
EBITDA Margin
-4735.97%
TTM Avg
-4735.97%
3Y Avg
-4735.97%
5Y Avg
-4735.97%
Market Cap
$110.13M
EBITDA Margin
-624817.90%
TTM Avg
-624817.90%
3Y Avg
-624817.90%
5Y Avg
-624817.90%
Market Cap
$109.45M
EBITDA Margin
28.85%
TTM Avg
28.85%
3Y Avg
28.85%
5Y Avg
28.85%
Market Cap
$108.73M
EBITDA Margin
-10.96%
TTM Avg
-24.45%
3Y Avg
-32.87%
5Y Avg
-38.11%
Market Cap
$108.20M
EBITDA Margin
-6164.17%
TTM Avg
-4620.17%
3Y Avg
-2654.54%
5Y Avg
-2163.85%
Market Cap
$114.08M
EBITDA Margin
-121.55%
TTM Avg
-120.84%
3Y Avg
-101.07%
5Y Avg
-82.00%
Market Cap
$107.80M
EBITDA Margin
5.60%
TTM Avg
2.28%
3Y Avg
0.00%
5Y Avg
-2.15%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $111.14M | -29.32% | -17.24% | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.05M | N/A | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $109.99M | -4735.97% | -4735.97% | -4735.97% | -4735.97% |
| Immunic, Inc. (IMUX)vs › | $110.13M | -624817.90% | -624817.90% | -624817.90% | -624817.90% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $109.45M | 28.85% | 28.85% | 28.85% | 28.85% |
| Apyx Medical Corporation (APYX)vs › | $108.73M | -10.96% | -24.45% | -32.87% | -38.11% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.20M | -6164.17% | -4620.17% | -2654.54% | -2163.85% |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | -121.55% | -120.84% | -101.07% | -82.00% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.80M | 5.60% | 2.28% | 0.00% | -2.15% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $114.74M | -254.86% | -347.69% | -398.28% | -4102.41% |
Gross Margin
12.8%
EBITDA Margin
-29.3%
Operating Margin
-33.2%
Net Margin
-52.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | 0.31% |
| 2025-09-30 | -39.49% |
| 2025-03-31 | -12.55% |
| 2024-03-31 | -0.99% |
